Avioq -Model HIV-1 -Microelisa System
The Avioq HIV-1 Microelisa System is intended for use as an aid in diagnosis of infection with HIV-1. It is not intended for use in screening blood donors. Developed as a standard two-step indirect microelisa system assay, the Avioq HIV-1 Microelisa System contains coated 96-well microwell plates, color-coded, liquid calibrator and positive control, and a ready-to-use liquid substrate. The sample diluent contains sample addition monitoring to allow visualization of color change upon sample addition to microwells.
Ease of Use
- Fast, convenient procedure suitable for automation
- No sample pre-dilution step
- Color-coded calibrator and positive control
- Sample addition monitoring
Time and Cost-Savings
- Excellent sensitivity and specificity in clinical trials providing reduced cost for confirmatory testing
- High correlation between initial and repeat duplicate results
- High positive predictive value that saves unnecessary confirmatory testing
- Direct dilution into microplate well
Confidence in Results
- Color-coded reagents with sample addition monitoring
- Excellent performance characteristics to provide the “Right Answer Sooner”
Instrument Flexibility
- 96-well microplate with 8-well strips
- 10 uL specimen volume for serum/plasma
- Consistent volumes for Wash Buffer, Conjugate, Substrate, and Stop solutions
Safety
- Specimen diluent (Dilsim III) contains HIV-1 inactivator for safe microplate handling
Derived from purified and inactivated HIV-1 viral lysate proteins, the Avioq HIV-1 Microelisa System is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of antibodies to HIV-1 (a leading causal agent of AIDS in the U.S.) in human specimens collected as serum, plasma, dried blood spots, or oral fluid specimens obtained with the OraSure® HIV-1 Oral Specimen Collection Device.
Kit Configuration and Principle of Test
The product is available in three kit configurations, the 384, 960, and 9600 test kits. Please refer to the `Literature` tab for additional information, as well as the performance characteristics of this product. The Package Insert is available on the `Support` menu tab.
The Avioq HIV-1 Microelisa System uses HIV-1 antigens, including inactivated, purified HIV-1 viral lysate proteins, which are coated on the wells of microwell plates, for the detection of antibodies against HIV-1. Upon addition of a diluted test specimen containing antibodies to HIV-1 to a microwell, immune complexes are formed through the interaction between the anti- HIV in the specimen and the HIV antigens coated on the microwell.
Following incubation, the specimen is aspirated and the well is washed with buffer. Subsequently, anti-human immunoglobulin (goat) conjugated with horseradish peroxidase (HRP) is added which binds to the anti-HIV antigen complex during a second incubation. Following a wash and incubation with ABTS (2,2’-azino-di-(3-ethylbenzthiazoline-6-sulfonate)) substrate, a green color is produced. The enzyme reaction is stopped by the addition of a fluoride solution.
The amounts of antibodies to HIV present in the specimen are qualitatively proportional to color intensity. Because of the use of HIV-1 viral lysate as the primary antigens in the test, significant cross-reactivity with HIV-2 specimens was observed.